Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC is a phase 1/2, randomised interventional study registered as NCT07365592 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 138 participants, started 2026-04-09 and due to reach its primary completion in 2029-12-01. Interventions recorded: Oxaliplatin; Capecitabine; Anti-PD-1 monoclonal antibody; Sitagliptin (DPP4 inhibitor). Conditions listed: Colorectal Cancer. Primary outcome: Adverse events (AEs); Dose limiting toxicities (DLTs); Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1). Colorectal eligibility wording from the registry: "* Pathologically diagnosed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.